Beta Bionics (NASDAQ:BBNX – Get Free Report) and Olympus (OTCMKTS:OCPNY – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.
Analyst Ratings
This is a breakdown of recent recommendations for Beta Bionics and Olympus, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Beta Bionics | 1 | 4 | 9 | 1 | 2.67 |
| Olympus | 0 | 0 | 1 | 0 | 3.00 |
Beta Bionics presently has a consensus price target of $23.69, suggesting a potential upside of 43.07%. Given Beta Bionics’ higher possible upside, equities analysts plainly believe Beta Bionics is more favorable than Olympus.
Risk and Volatility
Beta Bionics has a beta of 3.44, indicating that its stock price is 244% more volatile than the S&P 500. Comparatively, Olympus has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.
Profitability
This table compares Beta Bionics and Olympus’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Beta Bionics | -65.31% | -27.33% | -24.28% |
| Olympus | 13.80% | 24.30% | 9.30% |
Valuation and Earnings
This table compares Beta Bionics and Olympus”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Beta Bionics | $100.25 million | 8.98 | -$73.20 million | ($1.84) | -9.00 |
| Olympus | $7.74 billion | 2.99 | $1.03 billion | $0.82 | 21.95 |
Olympus has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Olympus, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
0.0% of Olympus shares are held by institutional investors. 5.3% of Beta Bionics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Olympus beats Beta Bionics on 9 of the 15 factors compared between the two stocks.
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.
About Olympus
Olympus Corp. engages in the manufacture and sale of precision machineries and instruments. It operates through the following segments: Medical, Scientific Solutions, Imaging, and Others. The Medical segment covers digestive, surgical, and ultrasonic endoscopy as well as endoscopic treatment tools. The Scientific Solutions segment manufactures and sells biological and industrial microscopes, industrial endoscopes, and non-destructive testing equipment. The Imaging segment deals with digital cameras and recording devices. The Others segment includes biomaterial manufacturing and sales business. The company was founded by Takeshi Yamashita on October 12, 1919 and is headquartered in Tokyo, Japan.
Receive News & Ratings for Beta Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beta Bionics and related companies with MarketBeat.com's FREE daily email newsletter.
